Influence of hepatocarcinoma surveillance programs on cirrhotic patient’s survival: a real life study.

Resumen Background: Hepatocellular carcinoma (HCC) represents 75%-85% of all primary liver cancers and the third most common cause cancer-related death worldwide. Cirrhosis is relevant risk factor for HCC with 70%-90% cases diagnosed at end-stage disease. Several studies have revealed that early diagnosis under surveillance improves both prognosis availability major curative options. Aim:to determine current impact on survival a university hospital. Methods: we retrospectively gathered between Jan 2012 May 2018 hospital in Málaga(Spain). Inclusion criteria were space-occupying lesions (SOL) our centre exclusion non-HCC SOL before or after given dates. Epidemiological, etiological, liver-function, clinical, tumor-related, therapeutic response-to-treatment variables collected. Results: 159 patients finally included. 92.5% cirrhotic patients. Following Barcelona Clinic Liver Cancer (BCLC) staging classification, 73% who underwent 0, A B stages, whereas 38% didn’t perform stages. The surveillance-applying cluster had 33 months median while not-surveillance cohort showed 6 months. stages (0 A) [50 months], stage (20 months), C (10 months) D (2 statistically significant differences. Conclusions:HCC programs allow favorable tumor increasing chances treatment options, life expectancy